Contact us

  • Who we are
    • Our business model
    • Our leadership
  • What we do
    • Data foundations
    • Target identification
    • Drug programmes
      • Atopic dermatitis
      • Ulcerative colitis
    • Publications
  • Partnering
    • AstraZeneca
  • Sustainability
    • COVID-19
    • Data Diversity Initiative
    • AI principles
  • Investors
    • Announcements
      • Announcement alerts
    • Reports and presentations
    • General meetings
    • Governance
    • Business combination
    • Financial calendar
    • Investor resources
    • Analyst coverage
  • News and media
    • Press releases and in the media
    • Blog and videos
    • Events
    • Newsletter
    • Press kit
  • Careers
    • Culture blog
    • Join our team
    • Internships
Contact us
    • Our business model

      Who we are

      We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.

      Who we are
    • Our leadership

      Who we are

      We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.

      Who we are
    Who we are

    Who we are

    We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.

    Who we are
    • Data foundations

      What we do

      From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

      What we do
    • Target identification

      What we do

      From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

      What we do
      • Atopic dermatitis

        What we do

        From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

        What we do
      • Ulcerative colitis

        What we do

        From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

        What we do
      Drug programmes

      What we do

      From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

      What we do
    • Publications

      What we do

      From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

      What we do
    What we do

    What we do

    From target identification through to clinical development, our AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success.

    What we do
    • AstraZeneca

      Partnering

      We partner with leading pharmaceutical and biotech companies to tackle therapeutic challenges from new angles and develop novel drugs for complex multifactorial diseases.

      Partnering
    Partnering

    Partnering

    We partner with leading pharmaceutical and biotech companies to tackle therapeutic challenges from new angles and develop novel drugs for complex multifactorial diseases.

    Partnering
    • COVID-19

      Sustainability

      BenevolentAI is committed to weaving environmental, social and governance (ESG) stewardship into the fabric of our mission.

      Sustainability
    • Data Diversity Initiative

      Sustainability

      BenevolentAI is committed to weaving environmental, social and governance (ESG) stewardship into the fabric of our mission.

      Sustainability
    • AI principles

      Sustainability

      BenevolentAI is committed to weaving environmental, social and governance (ESG) stewardship into the fabric of our mission.

      Sustainability
    Sustainability

    Sustainability

    BenevolentAI is committed to weaving environmental, social and governance (ESG) stewardship into the fabric of our mission.

    Sustainability
      • Announcement alerts

        Investors

        Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

        Investors
      Announcements

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Reports and presentations

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • General meetings

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Governance

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Business combination

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Financial calendar

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Investor resources

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    • Analyst coverage

      Investors

      Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

      Investors
    Investors

    Investors

    Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

    Investors
    • Press releases and in the media

      News and media

      Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

      News and media
    • Blog and videos

      News and media

      Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

      News and media
    • Events

      News and media

      Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

      News and media
    • Newsletter

      News and media

      Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

      News and media
    • Press kit

      News and media

      Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

      News and media
    News and media

    News and media

    Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

    News and media
    • Culture blog

      Careers

      Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.

      Careers
    • Join our team

      Careers

      Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.

      Careers
    • Internships

      Careers

      Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.

      Careers
    Careers

    Careers

    Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.

    Careers

Sitemap

  • Home
  • Sitemap
  • Home
  • Who we are
    • Our business model
    • Our leadership
  • What we do
    • Data foundations
    • Target identification
    • Drug programmes
      • Atopic dermatitis
      • Ulcerative colitis
    • Publications
  • Partnering
    • AstraZeneca
  • Sustainability
    • COVID-19
    • Data Diversity Initiative
    • AI principles
  • Investors
    • Announcements
      • Announcement alerts
    • Reports and presentations
    • General meetings
    • Governance
    • Business combination
    • Financial calendar
    • Investor resources
    • Analyst coverage
  • News and media
    • Press releases and in the media
    • Blog and videos
    • Events
    • Newsletter
    • Press kit
  • Careers
    • Culture blog
    • Join our team
    • Internships
  • Terms and conditions
  • Privacy policy
  • Cookie declaration
  • Accessibility
  • Sitemap

Contact us

Registered address
9 rue de Bitbourg
L-1273 Luxembourg
Grand Duchy of Luxembourg

  • Drug programmes
  • Partnering
  • Investors
  • Careers
  • Terms and conditions
  • Privacy policy
  • Cookie declaration
  • Accessibility
  • Sitemap

Company registration: R.C.S. Luxembourg: B255412

©BenevolentAI 2023